MBX
MBX Biosciences, Inc.
57.72
+1.39 (+2.47%)
52w low 23.07
72.64 high
69.9% of range
Financial Analysis
| (USD) | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 21.80M | 23.93M | 25.80M | 27.27M | 40.93M | |
| R&D | 17.72M | 19.27M | 19.76M | 18.47M | 30.98M | |
| SG&A | 4.08M | 4.66M | 6.04M | 8.79M | 9.95M | |
| Operating Income | -21.80M | -23.93M | -25.80M | -27.27M | -40.93M | |
| EBITDA | -21.74M | -23.88M | -25.73M | -27.20M | -40.85M | |
| Pretax Income | -19.41M | -21.62M | -22.06M | -23.52M | -37.09M | |
| Net Income | -19.41M | -21.62M | -22.06M | -23.52M | -37.09M | |
| EPS Diluted | -0.58 | -0.63 | -0.49 | -0.50 | -0.78 | |
| Diluted Shares | 33.45M | 34.20M | 44.87M | 46.58M | 47.70M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
--